These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34591292)

  • 1. Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
    Honda T; Yamaoka M; Terao YM; Hasegawa D; Kumamoto T; Takagi M; Yoshida K; Ogawa S; Goto H; Akiyama M
    Int J Hematol; 2022 Jan; 115(1):140-145. PubMed ID: 34591292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatosplenic alphabeta T cell lymphoma.
    Nagai Y; Ikegame K; Mori M; Inoue D; Kimura T; Shimoji S; Togami K; Tabata S; Kurata M; Imai Y; Matsushita A; Nagai K; Ogawa H; Takahashi T
    Int J Clin Oncol; 2010 Apr; 15(2):215-9. PubMed ID: 20217452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
    Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.
    Voss MH; Lunning MA; Maragulia JC; Papadopoulos EB; Goldberg J; Zelenetz AD; Horwitz SM
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):8-14. PubMed ID: 23107915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
    Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
    Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatosplenic γδ T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults.
    McThenia SS; Rawwas J; Oliveira JL; Khan SP; Rodriguez V
    Pediatr Transplant; 2018 Aug; 22(5):e13213. PubMed ID: 29921021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
    Yu ZP; Ding JH; Sun AN; Chen BA; Ge Z; Wu DP
    Stem Cells Dev; 2019 Oct; 28(20):1376-1383. PubMed ID: 31464164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma.
    Sumi M; Takeda W; Kaiume H; Kirihara T; Kurihara T; Sato K; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Kobayashi H
    Leuk Lymphoma; 2015 Apr; 56(4):1140-2. PubMed ID: 25065703
    [No Abstract]   [Full Text] [Related]  

  • 10. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
    Tang W; Fan X; Wang L; Hu J
    Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
    Krejci M; Doubek M; Brychtova Y; Stehlikova O; Chovancova J; Tichy B; Francova HS; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Jan; 92(2):249-54. PubMed ID: 23014659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
    Yamaguchi M; Kotani T; Nakamura Y; Ueda M
    Int J Hematol; 2006 Jun; 83(5):450-3. PubMed ID: 16787878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
    Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
    Okuni M; Yakushijin K; Uehara K; Ichikawa H; Suto H; Hashimoto A; Tanaka Y; Shinzato I; Sakai R; Mizutani Y; Nagao S; Kurata K; Kakiuchi S; Miyata Y; Inui Y; Saito Y; Kawamoto S; Yamamoto K; Ito M; Matsuoka H; Minami H
    Intern Med; 2019 Mar; 58(5):707-712. PubMed ID: 30449784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatosplenic T-cell lymphoma presented with massive splenomegaly and pancytopenia - a case report.
    Sukrisman L; Rajabto W; Harahap AS; Fanggidae ESDE; Ham MF; Priantono D
    Klin Onkol; 2023; 36(3):246-250. PubMed ID: 37353354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
    Yabe M; Medeiros LJ; Tang G; Wang SA; Ahmed S; Nieto Y; Hu S; Bhagat G; Oki Y; Patel KP; Routbort M; Luthra R; Fanale MA; Bueso-Ramos CE; Jorgensen JL; Vega F; Chen W; Hoehn D; Konoplev S; Milton DR; Wistuba I; Li S; You MJ; Young KH; Miranda RN
    Am J Surg Pathol; 2016 May; 40(5):676-88. PubMed ID: 26872013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatosplenic gamma/delta T-cell lymphoma with isochromosome 7q, translocation t(7;21), and tetrasomy 8 in a 9-year-old girl.
    Rossbach HC; Chamizo W; Dumont DP; Barbosa JL; Sutcliffe MJ
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):154-7. PubMed ID: 11990705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
    Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
    Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
    Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.